Maurice BERENGER, MBA. He has graduated from Ecole Normale Superieure in physics and earned an MBA from INSEAD, France. He joined Defymed board in December 2011 and brings more than two decades of international experience in the medical device sector, he focuses on strategic issues facing Defymed and advises Defymed management regarding funding opportunities. Maurice is currently the CEO of PROTIP SA , an innovative medical device company focusing on laryngology, he is also the chairman of Endotools therapeutics (Belgium). Prior to his entrepreneurial experience Maurice held various international positions within Guidant (which was later sold to Abbott and Boston Scientific).
Michel PINGET, MD, PhD. Professor, head of the department of Endocrinology, Diabetes and Metabolic Diseases at the “Strasbourg University hospitals”, since 1996. He is the president of the CeeD since 1991. He has been working on MAILPAN®’s project since 1996. He is the former president of the AIDPIT (Artificial Insulin Delivery Pancreas and Islet Transplantation), an EASD working group. He is one of the first diabetologists who implanted an insulin pump in France (1989).He is a world known opinion leader in the diabetes field.
Jean-François Rax, Director of Investments at Alsace Capital. Jean-François Rax is a graduate from INSA (Lyon), joined Alsace Capital in April 2014 as Investment Manager of the seed fund Cap Innov’Est. Prior to joining Alsace Capital and since 2008, Jean-François was an Associate at Inserm Transfert Initiative, French seed fund dedicated to life sciences and human health. Owing to his previous experiences, he has also a solid background in company creation, technology transfer, licensing and marketing strategy.
Laurent Bocahut joined Emertec in 2015 as managing partner and member of the executive committee. He is responsible for managing Emertec funds dedicated to innovative material technology in the industry and medtech sectors (ie. the “Fonds Lorrain des Matériaux” and “Fonds Européen des Matériaux”). Laurent graduated from Ecole Polytechnique in 2002 and holds a Masters of Science degree in Environmental Engineering from the University of Illinois at Urbana-Champaign. He started his professional career within the AREVA group where he held several management positions from 2004 to 2008.
In 2008, he was introduced to venture capital in the context of an entrepreneurial project and subsequently joined the “Fonds Lorrain des Matériaux” as Investment Manager in 2009. Since then Laurent has led more than a dozen venture capital investment deals with innovative start-ups and SMEs in eastern France, Belgium, Germany and Switzerland. In august 2015, Laurent’s initiative to raise a new venture capital fund dedicated to early stage material technologies resulted in the first closing of “Fonds Européen des Matériaux” with € 21 million under management.
Pascal Neuville, PhD is CEO of Domain therapeutics. He has a PhD in molecular biology from University of Strasbourg, France. He spent five years at the University of Geneva as a post doc and then as Assistant Professor. Pascal then joined Transgene SA as an R&D project leader. From 2002 to 2008, he was CSO of Faust Pharmaceuticals SA, a drug discovery and development company in CNS. He founded Domain Therapeutics in 2008. From 2008 to 2010, Pascal was President of Alsace BioValley’s Board of Directors, the life science competitiveness cluster of Alsace, and continued as a board member from 2010 to 2014. He is also a member of the investment committee of SATT CONECTUS, the private TTO of the University of Strasbourg and regional research institutions, and sits on the board of Axilum Robotics, another medtech